688505.SH
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co., Ltd.
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 8.38
−3.01%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 667.0M | 685.8M | 709.4M | 850.7M | 1.0B |
| Cost of Revenue | 72.9M | 69.3M | 61.2M | 70.6M | 84.1M |
| Gross Profit | 594.1M | 616.5M | 648.2M | 780.1M | 947.1M |
| Operating Expenses | |||||
| R&D Expense | 305.3M | 357.9M | 314.2M | 243.8M | 226.9M |
| SG&A Expense | 90.2M | — | — | — | — |
| General & Admin Expense | 30.5M | 40.4M | 41.7M | 42.9M | 44.9M |
| Selling & Marketing Expense | 286.1M | 395.1M | 299.3M | 383.6M | 554.6M |
| Other Expenses | 1.7M | — | — | — | — |
| Total Operating Expenses | 718.9M | 799.1M | 657.6M | 671.9M | 824.4M |
| Cost and Expenses | 791.8M | 868.4M | 718.8M | 742.5M | 908.5M |
| Operating Income (EBIT) | (126.6M) | (155.4M) | 2.4M | 97.1M | 133.3M |
| Non-Operating | |||||
| Interest Income | 4.0M | — | — | — | — |
| Interest Expense | 117.1K | — | — | — | — |
| Net Interest Income | 3.9M | — | — | — | — |
| Other Non-Op Income/Expense | 2.2M | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (124.8M) | (155.9M) | 5.5M | 97.5M | 132.3M |
| Income Tax Expense | — | 1.9M | (34.0M) | (10.9M) | (5.0M) |
| Bottom Line | |||||
| Net Income | (126.4M) | (157.4M) | 39.7M | 108.6M | 138.0M |
| Earnings from Cont. Ops | (126.7M) | (157.7M) | 39.4M | 108.4M | 137.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (126.4M) | (157.4M) | 39.7M | 108.6M | 138.0M |
| Per Share | |||||
| Basic EPS | CN¥0.03 | (CN¥0.15) | CN¥0.04 | CN¥0.11 | CN¥0.13 |
| Diluted EPS | CN¥0.03 | (CN¥0.15) | CN¥0.04 | CN¥0.11 | CN¥0.13 |
| Revenue Per Share | CN¥0.64 | — | — | — | — |
| Shares | |||||
| Basic Shares Outstanding | 1.0B | — | — | — | — |
| Diluted Shares Outstanding | 1.0B | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | 45.5M | (82.8M) | 76.7M | 151.3M | 207.3M |
| D&A | 18.7M | 72.6M | 74.3M | 54.2M | 74.1M |
| EBIT | 26.8M | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026